Telos Capital Management Inc. Purchases 9,670 Shares of Edwards Lifesciences Corporation $EW

Telos Capital Management Inc. raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 15.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,085 shares of the medical research company’s stock after acquiring an additional 9,670 shares during the quarter. Telos Capital Management Inc.’s holdings in Edwards Lifesciences were worth $5,606,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Rosenberg Matthew Hamilton acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $28,000. True Wealth Design LLC boosted its holdings in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares in the last quarter. NewSquare Capital LLC boosted its holdings in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 57,824 shares of company stock worth $4,863,323 over the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the topic of several research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a report on Thursday, December 18th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 12th. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $98.00 price target (up from $95.00) on shares of Edwards Lifesciences in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $96.82.

Edwards Lifesciences Trading Down 0.7%

EW opened at $82.08 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The firm has a market capitalization of $47.63 billion, a PE ratio of 35.38, a P/E/G ratio of 3.18 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company’s 50-day moving average is $84.62 and its 200 day moving average is $81.11.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.